Tissue Regenix Group (LSE:TRX) Total Debt per Share: £0.11 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Tissue Regenix Group Total Debt per Share?

Tissue Regenix Group LSE:TRX Total Debt per Share is £0.11 as of Jun. 2025. The stock has 7 warning signs investors should review.

£0.11 (As of Jun. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Tissue Regenix Group's Total Debt Per Share for the quarter that ended in Jun. 2025 was £0.11.

Tissue Regenix Group Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group Total Debt per Share Chart

Tissue Regenix Group Annual Data
Trend Jan15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.08 0.11 0.11 0.12

Tissue Regenix Group Semi-Annual Data
Jul14 Jan15 Jul15 Jan16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.11 0.12 0.12 0.11

Tissue Regenix Group Total Debt per Share Calculation

Tissue Regenix Group's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(7.87+0.49)/71.23
=0.12

Tissue Regenix Group's Total Debt Per Share for the quarter that ended in Jun. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(7.61+0.42)/71.23
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of £0.11 mean?
Tissue Regenix Group (LSE:TRX) has a Total Debt per Share of £0.11 as of Jun. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's Total Debt per Share too high?
Tissue Regenix Group's current Total Debt per Share is £0.11.
How does Tissue Regenix Group's Total Debt per Share compare to VRTX and REGN?
Tissue Regenix Group's Total Debt per Share of £0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Tissue Regenix Group and its competitors. Tissue Regenix Group's current Total Debt per Share is £0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (LSE:TRX) has a current Total Debt per Share of £0.11. The stock's GF Value™ is £0.87, compared to a current price of £0.07 — trading 91.7% below its estimated fair value. The current Total Debt per Share is £0.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Tissue Regenix Group (LSE:TRX), the current Total Debt per Share is £0.11 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a UK-based medical technology company that develops, processes, and commercializes regenerative tissue products for surgical and clinical applications. It uses two proprietary platform technologies, dCELL and BioRinse, to produce acellular biological scaffolds and tissue-based implants. Its product portfolio spans musculoskeletal, dermis, soft tissue, and birth tissue applications, including the OrthoPure range of soft tissue products. The company's principal processing and manufacturing operations are located in San Antonio, Texas, where most dCELL and BioRinse products are made, alongside a facility in Leeds, United Kingdom, focused on porcine soft tissue processing. Tissue Regenix sells primarily to hospitals, surgeons, and healthcare providers, generating most of its revenue in the United States, with additional sales across other international markets. Revenue comes from the sale of its regenerative medical devices and tissue products.